Pharmaceutical company PARI Pharma received marketing authorization from the European Commission for its nebulizer Vantobra, a breakthrough therapy for patients who suffer from cystic fibrosis (CF). The product is a novel and highly concentrated tobramycin therapeutic option for inhalation that uses a Tolero nebulizer, and will now be commercialized in…
cystic fibrosis
Travel Lake Anna might look like a typical travel agency dedicated to promoting vacations around Lake Anna, a state park located in Virginia. However, the company has a unique business model and purpose. Husband and wife team Chris and Laura Denkers created and manage the company in support of their two sons who were…
AffloVest, a wearable, self-contained oscillation vest device from International Biophysics that helps patients with Cystic Fibrosis breathe easier, was previously backed by numerous patient testimonies and is now proven in a new Clinical Study that it increased forced expiratory volume in one second (FEV1) an average…
A new study published in Experimental Physiology is providing insights into muscle strength impairment in patients with cystic fibrosis (CF). A joint team of researchers from University of Georgia and Georgia Regents University led by Dr. Melissa Erickson used a novel approach to the study of muscle strength…
Could a Bilateral Lung and Pancreatic Transplantation From the Same Donor Benefit CFRD Patients?
A team led by researchers at the University Hospital in Strasbourg, France is currently recruiting patients for a clinical trial designed to assess the efficacy of combined lung and pancreatic islet transplantation in individuals with end-stage cystic fibrosis (CF). The trial is entitled “Metabolic…
Researchers at the University of Michigan Medical School recently published in the journal Microbiome findings indicating that lung microbiota alterations observed during disease onset in individuals with cystic fibrosis may become useful as predictors of exacerbations. The study is entitled “The daily dynamics of…
An article published in BioMed Central’s Pulmonary Medicine journal provides evidence that the impaired immune system, a key feature in cystic fibrosis (CF), may lead to patients being deprived of necessary oxygen due to lung tissue destruction. The study, entitled “Hypoxia down-regulates expression…
Aridis Names New Chief Medical Officer To Lead Development of CF Treatment of Pseudomonas Aeruginosa
Biopharmaceutical company Aridis Pharmaceuticals, Inc. has named Paul-Andre de Lame, MD as its new chief medical officer to help the company in their efforts to develop new anti-infective and immune therapies to treat infectious diseases. Aridis is currently developing a reactive monoclonal antibody drug called Aerucin, to treat Pseudomonas aeruginosa associated with cystic fibrosis.
AbbVie recently announced that the 2015 AbbVie CF Scholarship is now open and accepting applications from both graduate and undergraduate students. This scholarship supports and honors young adults suffering with cystic fibrosis (CF) in their pursuit of higher education. Students can apply for the scholarship until May 27, 2015, 10 a.m. (central…
In a new study entitled “Ultrasound echo-intensity predicts severe pancreatic affection in cystic fibrosis patients,” the authors suggest ultrasonography is a suitable and effective diagnostic tool to evaluate pancreatic function in cystic fibrosis patients. The findings could help physicians better diagnose and treat the pancreatic issues and…
Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Recent Posts
- Trikafta helps cystic fibrosis patients reduce supportive treatments: Survey December 23, 2025
- Genetic analysis points to new clues behind pain in cystic fibrosis December 22, 2025
- CF gene therapy 4D-710 shows signs of improving lung function in early trial December 18, 2025
- My late daughter is still teaching me resilience today December 17, 2025
- Small study finds GLP-1 drugs boost lung function in CF patients December 16, 2025